Mbx Biosciences ceo Steven Hoerter sells $268,234 in shares

Steven L. Hoerter, the Chairman, President, and CEO of MBX Biosciences, Inc., divested 4,893 shares of the company's common stock for a total value of $268,234 on November 10, 2026. The shares were sold at a weighted average price of $54.82 per share, within a price range of $51.52 to $55.29. This transaction was conducted to settle tax liabilities arising from the vesting of restricted stock units under a mandatory sell-to-cover agreement with the company.

Currently, the stock is trading at $55.94, marking an 8.9% gain over the past week and a 126% return over the previous year. Post-transaction, Hoerter directly owns 78,045 shares of MBX Biosciences common stock, with an additional 20,000 shares held indirectly through the Steven L Hoerter Revocable Trust. According to InvestingPro analysis, the stock is currently fairly valued.

MBX Biosciences has garnered significant attention from several analyst firms. Citizens has assigned a Market Outperform rating with a price target of $86, citing promising data from MBX-4291, an injectable obesity treatment. Truist Securities has maintained a Buy rating with a price target of $88, highlighting the drug's favorable risk/reward profile ahead of its data readout expected in Q4 2026.

Stifel has also increased its price target to $84, retaining a Buy rating due to positive Phase 1 trial results for MBX-4291, including a smooth pharmacokinetic profile and high tolerability. The company has also appointed Peter Radovich as an independent director, bringing the total board members to eight, per a recommendation from the Nominating and Corporate Governance Committee.